Continued SRI for Obsessive-Compulsive Disorder

Phase-Based Progress Estimates
Obsessive-Compulsive Disorder+5 More
Cognitive Behavioral Therapy - Behavioral
< 18
All Sexes
What conditions do you have?

Study Summary

The purpose of this study is to examine whether youth with OCD who benefit from CBT augmentation to SRI can discontinue their medication without relapse over 24 weeks.

Eligible Conditions
  • Obsessive-Compulsive Disorder
  • Obsessive compulsive behavior
  • Cognitive Behavioral Therapy

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: 7 days

7 days
Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS)
Clinical Global Impression-Improvement

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

2 Treatment Groups

Continued SRI
1 of 2
Discontinuation titration to placebo
1 of 2

Active Control

Non-Treatment Group

200 Total Participants · 2 Treatment Groups

Primary Treatment: Continued SRI · Has Placebo Group · N/A

Discontinuation titration to placebo
PlaceboComparator Group · 1 Intervention: Cognitive Behavioral Therapy · Intervention Types: Behavioral
Continued SRI
ActiveComparator Group · 1 Intervention: Cognitive Behavioral Therapy · Intervention Types: Behavioral

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 7 days

Who is running the clinical trial?

Baylor College of MedicineLead Sponsor
914 Previous Clinical Trials
5,981,839 Total Patients Enrolled
12 Trials studying Obsessive-Compulsive Disorder
795 Patients Enrolled for Obsessive-Compulsive Disorder

Eligibility Criteria

Age < 18 · All Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
The child has a Full Scale IQ ≥ 85 on the WASI.
You are a resident of Texas.
You have a child that meets the inclusion criteria 1, 2, 3 above.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 1st, 2021

Last Reviewed: November 21st, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.